Our specialty infusion products include the latest breakthrough oncology drugs produced in a USP 800-compliant facility.

Avella’s 503A compounding services give physicians, hospitals and payers a cost-effective way to provide safe, powerful drugs to hematology and oncology patients. Our patient-specific, unit-dose chemotherapy drugs are used in IV or other specialized administration. Given that these chemotherapeutics are hazardous drugs with a narrow therapeutic index, they must be produced in a facility with the highest standards for safety and quality. Avella meets that need by employing highly-trained oncology pharmacists and maintaining compliance with USP 800 throughout our 5,000-square-foot compounding facility.

As a result, hospitals can outsource these complex, powerful medications without the need to build and staff a facility that complies with these standards. This reduces pharmacy overhead and frees up resources to be used internally where they are needed most. Oncology physicians also have a partner they can trust, thanks to the expertise of our staff and our excellent track record for safety. In addition, we use a proprietary ordering, dosing and pathway compliance software which ensures accuracy throughout all of these processes. The end result is best-in-class patient care, safety, quality and outcomes.

Avella also strives to make the entire ordering process easy and convenient for our customers. Because we compound overnight, we’re able to receive a specific order and then mix, pack and ship it the same day. So our customers always get the right amount of medication at the right time.

Contact an Avella 503A Specialist